RxDoctor Payments Data

Howard Bush, MD

Interventional Cardiology · Weston, FLNPI 1598725954

Payments from drug & device makers

$2,504in general payments, 2019–2025

Across 77 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$542
  • Novartis$419
  • Cardiva Medical, Inc.$365
  • Boston Scientific$364
  • Abbott$196
  • Biosense Webster, Inc.$152
  • plus $466 from 6 others

What the payments were for

  • Food & beverage$2,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,504 in reported general payments places this provider in the 15th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$169,984
Medicare patients
883
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$244,099
XareltoRivaroxaban80$98,678
Repatha SureclickEvolocumab71$73,130
EntrestoSacubitril/Valsartan31$50,785
Rosuvastatin Calcium374$5,914
Acebutolol Hcl64$5,744
Atorvastatin Calcium464$4,996
Metoprolol Succinate279$4,030
Losartan Potassium291$3,239
Dofetilide13$3,176
Amlodipine Besylate287$2,555
ClopidogrelClopidogrel Bisulfate157$2,361
Ezetimibe89$2,354
Carvedilol199$2,032
Ezetimibe-SimvastatinEzetimibe/Simvastatin21$1,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$419$50,78531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →